Media Advisory For Federal Appeals Court – Psilocybin Case Hearing

Media Advisory For Federal Appeals Court – Psilocybin Case Hearing

Link to oral arguments: https://youtu.be/39MhxZ8SQ0U

Article about the hearing: https://www.marijuanamoment.net/federal-court-hears-case-challenging-dea-decision-to-deny-psilocybin-rescheduling-petition-without-consulting-health-officials/?fbclid=IwAR139IISoWU1peXCNr04xgkM3N9rgCk9OybBMI3-hxkY7AAABbyGD373YnA

An interview I gave on awake.net: https://awake.net/aims-vs-dea-right-to-try-psilocybin-for-end-of-life-court-hearing-of-deas-denial-on-petition-to-reschedule-psilocybin-friday-oct-20-2023-9-am-phoenix-azhttps-youtu-be-ud1vsa69e6msitufvgxoy/

Media Advisory

  • Right to Try and psychedelics subject matter experts are available for interviews or quotes about the Ninth Circuit Court of Appeals case, Aggarwal v. Drug Enforcement Agency (DEA).
  • The case seeks federal court review of the DEA’s denial of a petition to reschedule psilocybin (commonly called magic mushrooms) from a highly restricted Schedule I drug to a less restricted Schedule II so that it can be accessed by physicians and other providers to help those with terminal and other life-threatening conditions.
  • This case focuses on DEA’s long history of applying an inaccurate test to rescheduling petitions. The outcome of this case could have implications for other emerging and promising therapies.
  • A live stream of the argument will be available October 20, 2023 at 9:00 a.m. MST at https://www.ca9.uscourts.gov/media/live-oral-arguments/

Available for Comment

kathryn@yournpa.org

  • Matthew C. Zorn, YETTER COLEMAN LLP, 713.632.8064, mzorn@yettercoleman.com

(counsel presenting argument)

spennington@porterwright.com

Additional Background

On Friday, October 20, 2023, at 9:00 AM MST in Phoenix, Arizona, the Ninth Circuit Court of Appeals will hear arguments in Aggarwal v Drug Enforcement Agency (DEA) (No. 22-1718; AIMS III).

The case seeks federal court review of the DEA’s denial of a petition to reschedule psilocybin from a highly restricted Schedule I drug to a less restricted Schedule II category.

Dr. Sunil Aggarwal, a Seattle palliative care physician and co-founder of the Advanced Integrative Medical Science Institute (AIMS), and several of his patients with advanced cancer sought access to psilocybin, an investigational drug shown to offer remarkable relief from anxiety and depression in terminally ill patients.

As a Schedule I drug, Psilocybin can only be accessed with the DEA’s permission. Initially, Dr. Aggarwal sought permission under state and federal Right to Try (RTT) laws, which legislatures enacted to facilitate access to promising investigational drugs to patients with life-threatening conditions.

During a lawsuit related to RTT (AIMS I), the DEA suggested that Dr. Aggarwal file a rescheduling petition. He did so, filing a nine-page petition. DEA denied the Petition with four sentences.

The Court will consider whether the DEA’s denial was unlawful and may order the DEA to refer the petition to Health and Human Services (FDA) for further medical and scientific evaluation.

About the National Psychedelics Foundation

The NPA Foundation is a registered 501(c)(3) non-profit organization dedicated to educating and supporting those providing Psychedelic Assisted Care. Our mission is to guide providers through the opportunities, risks, and legal complexities inherent in the field. We focus on three core pillars: Accessibility, Affordability, and Availability.

We engage in various activities and programs to achieve our mission, including legal and regulatory guidance, financial empowerment and support, and community engagement. We collaborate with research institutions, policymakers, and the community to advocate for evidence-based policies and practices in Psychedelic Assisted Care.

For more information visit yournpa.org 10-18-23 press release

Latest Blog Posts

A Holistic Solution to Health Disparities: Naturopathic Medicine and Culturally Competent Care 

A Holistic Solution to Health Disparities: Naturopathic Medicine and Culturally Competent Care 

Healthcare Disparities in African American Communities African Americans continue to face significant disparities in healthcare. From higher mortality rates for chronic conditions like cancer and heart disease to underdiagnosis of autoimmune disorders, these inequities stem from systemic racism, implicit bias, and a lack of cultural sensitivity among providers. Studies show that Black patients are less likely to receive adequate pain management and more likely to feel unheard or dismissed during medical visits. These disparities erode trust in the healthcare system and lead to poorer outcomes and avoidable suffering. For many, navigating the system can feel isolating and disempowering, leaving them ...

Read More
At AIMS Institute we prescribe low dose oral naltrexone for ‘long COVID’

At AIMS Institute we prescribe low dose oral naltrexone for ‘long COVID’

A recent paper in the Frontiers in Medicine states that An underutilized intervention for long  COVID is low dose naltrexone, which has an established safety profile for a variety of conditions. ‘Naltrexone is a non-selective opioid antagonist currently approved by the US Food and Drug Administration (FDA) for the treatment of alcohol and opioid dependence and is prescribed at 50–150 mg daily. At doses below 5 mg, it is considered low-dose naltrexone (LDN), exhibits anti-inflammatory and analgesic properties, and has been used off-label to reduce severity of symptoms in conditions such as fibromyalgia, multiple sclerosis, complex regional pain syndrome, myalgic encephalomyelitis/chronic fatigue ...

Read More
Unusual Suspects

Unusual Suspects

Psychedelic Therapies Gain New Advocates Texas Law Magazine Written by Robin Berghaus. Art by Matthieu Bourel Published November 6, 2024 Marcus Capone served seven combat tours as a Navy SEAL — including missions with SEAL Team Six, the nation’s preeminent counterterrorism unit — before being medically retired in 2013. For years, he struggled to find effective treatments for his traumatic brain injuries, depression, and post-traumatic stress disorder. Capone tried antidepressants, talk therapy, hyperbaric oxygen therapy, transcranial magnetic stimulation, and he visited several brain clinics. Nothing worked. When Capone’s life began falling apart, he considered suicide. His wife was just as ...

Read More
Call Us Text Us
Skip to content